The word steroids are always accompanied by negative comments and inquisitive looks. People have been wary because of its involvement in many controversies and issues throughout the years; and almost always, it involves the sports industry.

As we enter the 21st century, the abuse of anabolic steroids not only escalated, it also became prevalent outside the sports profession. It spread from bodybuilders and fitness instructors to image-conscious teenagers (read more). The youngest to be apprehended was a bunch of 8th graders, ages 15 to 17.

Many are familiar with its potential for misuse, but most are unaware of its medical use in treating several conditions. Anabolic steroids have been the savior of many patients. It helped relieve the symptoms of chronic diseases such as AIDS, myelofibrosis, and lupus. It aided patients suffering from muscle wasting like those undergoing chemotherapy and dialysis.

The appearance and performance-enhancing drug (APED) has many forms and derivatives. One of them is called oxymetholone.

What is oxymetholone?

Oxymetholone is an alkylated synthetic derivative of testosterone. It is one of the few steroids that earned the FDAs approval to be labeled as a prescribed drug, instead of a controlled substance. It is primarily used to treat muscle wasting and several kinds of anemia such as chemo-induced and aplastic anemia.

Like most steroids, oxymetholone has an anabolic-androgenic effect on the human body. The drug is available in the market with the trade names Anadrol 50 and Anapolon. You can only buy Anadrol by getting a medical prescription from your doctor or pharmacist.

How does it work?

Oxymetholones mechanism of action is unlike most anabolic steroids. Once orally ingested, it activates the androgen receptor-mediated signaling in our brain. This binding will start the stimulation of red blood cell production and protein synthesis. This will then promote hemoglobin production and formation of other blood cells. It will also increase the bodys bone density.

Oxymetholone does not bind well to the muscle cells receptor sites. This explains why muscle building and enhancement is only a secondary effect of the drug. But it still brings out the synthetic hormones androgenic effects like increased libido, muscle mass, hirsutism, and voice maturation.

What are its medical uses?

Before the discovery of immunosuppressive drugs, oxymetholone has been at the frontline of managing several chronic anemia cases. Some of its therapeutic benefits are as follows:

Aplastic anemia is a rare and chronic blood disorder that occurs due to stem cell damage inside the bone marrow. This prevents your bone marrow from producing the normal amount of blood cells to sustain your bodys needs. It is characterized as an autoimmune disorder, which means that your own body is producing antibodies to attack and destroy your own bone marrow.

Without treatment, patients will suffer from developing arrhythmia and eventually die from heart failure. Treatments that exist only suppresses the immune system to prevent further production of antibodies. Blood transfusion and the use of oxymetholone are also used to manage aplastic anemia.

The anabolic drug improved the patients hematopoietic development. It increases their RBC production as well as the number of reticulocytes inside the bone marrow.

Another case of blood disorder is the antithrombin deficiency. It is characterized by the production of abnormal blood clots, specifically in the deep veins of the legs.

Clotting should only happen if there is an injury or trauma in the blood vessels. Clots form a stopper-like device inside our body to prevent blood from exiting its vessels. The protein called anti-thrombin prevents our body from forming unnecessary and excessive clots during an injury.

Without it or at low levels, our body would not have a stop signal during clot formation. Thus, creating excessive clots throughout the body that can block the normal blood circulation.

Oxymetholone, in combination with warfarin, is used as a thrombolytic therapy for patients with ATIII deficiency. It augments the bodys fibrinolytic activity and anticoagulant properties.

Hereditary angioedema is a genetic disease characterized by severe swelling in the face, limbs, gastrointestinal tract, and airways. It is a fatal disease due to its common symptom of laryngeal edema. This edema involves the formation of airway and intestinal obstruction that disrupts the normal air delivery to the lungs.

Angioedema is caused by C1 inhibitor deficiency. This protein is found and produced in the bloods plasma or serum. With the use of oxymetholone therapy, a significant increase in the plasma levels of C1 inhibitors is observed. It also improves the level of C4 protein and prevents it from dropping to below normal levels.

The drug is administered to patients in an alternate-day manner. Managing the drug administration prevents side effects like mild virilization and insomnia from occurring.

Chronic weight loss is prevalent in patients undergoing antiretroviral therapy. It can be the medications side effect or from different metabolism alterations. The involuntary loss of weight makes HIV-infected individuals susceptible to opportunistic infections.

To combat this, doctors administered oxymetholone with the antagonist ketotifen to promote weight gain. However, oxymetholone therapy alone showed a much higher increase in the restoration of fat-free muscle mass. Improvements are faster together with proper food intake and mild exercise.

What are its side effects?

Like all medications, the long-term use and abuse of oxymetholone have severe consequences to the body. Fatal ones include the formation of blood-filled cysts or tumors in the liver and spleen. Some long-term aid effects also include:

Allergic reactions such as hives, face swelling, and breathing difficulties may occur during short-term use.

Individuals diagnosed with diabetes, kidney and liver disease, breast and prostate cancer, and cardiovascular diseases may suffer severe conditions if administered with anabolic steroids.

According to the law, oxymetholone must be used under strict medical supervision. Prescription labels should be followed, and dosages may only be changed by your doctor. Skipping or abruptly stopping the medication without consent is highly prohibited.

Read this article:
Where To Find Anadrol 50 (Oxymetholone) for Sale - FeastMagazine

Detailed market survey on the Global Autologous Stem Cell Based Therapies Market Research Report 2020-2026. It analyses the vital factors of the Autologous Stem Cell Based Therapies market supported present business Strategy, Autologous Stem Cell Based Therapies market demands, business methods utilised by Autologous Stem Cell Based Therapies market players and therefore the future prospects from numerous angles well. Business associatealysis could be a market assessment tool utilized by business and analysts to grasp the quality of an business. Autologous Stem Cell Based Therapies Market report It helps them get a sense of what is happening in an industry, i.e., demand-supply statistics, Autologous Stem Cell Based Therapies Market degree of competition within the industry, Autologous Stem Cell Based Therapies Market competition of the business with different rising industries, future prospects of the business.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

Obtain sample copy of Autologous Stem Cell Based Therapies market report: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#request-sample

The Global Autologous Stem Cell Based Therapies Market report is a fully analyzed and intelligent study of the international industry that focuses on a wide range of significant elements such as market size in terms of value and volume, regional growth analysis, competition and segmentation. It is considered as extraordinary findings that accountable to offer insightful details into some essential attributes related to the global Autologous Stem Cell Based Therapies Market 2020. The detailed investigation of this report has been carried out by the list of skillful researchers and investigators with a deep analysis of current industry trends, availability of distinct opportunities, drivers, openings and limitation that influence the Autologous Stem Cell Based Therapies Market on the global scale.

The Global Autologous Stem Cell Based Therapies market worth about xx billion USD in 2020 and it is expected to reach xx billion USD in 2026 with an average growth rate of x%. United States is the largest production of Autologous Stem Cell Based Therapies Market and consumption region in the world, Europe also play important roles in global Autologous Stem Cell Based Therapies market while China is fastest growing region.

Checkout Inquiry For Buying or Customization of Autologous Stem Cell Based Therapies Market Report: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#inquiry-for-buying

Geographically, Autologous Stem Cell Based Therapies market report is segmented into several key Regions, with production, consumption, revenue. The major regions involved in Autologous Stem Cell Based Therapies Market are (United States, EU, China, and Japan).

Leading companies reviewed in the Autologous Stem Cell Based Therapies report are:

RegeneusMesoblastPluristem Therapeutics IncU.S. STEM CELL, INC.Brainstorm Cell TherapeuticsTigenixMed cell Europe

Autologous Stem Cell Based Therapies Market Product Type Segmentation As Provided Below:The Autologous Stem Cell Based Therapies Market report is segmented into following categories:

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.The Autologous Stem Cell Based Therapies market report is segmented into Type by following categories;Embryonic Stem CellResident Cardiac Stem CellsUmbilical Cord Blood Stem Cells

The Autologous Stem Cell Based Therapies market report is segmented into Application by following categories;Neurodegenerative DisordersAutoimmune DiseasesCardiovascular Diseases

Reportedly, the massive growth graph in the research and development sectors will be liable to generate plenty of excellent opportunities in the upcoming years. The Autologous Stem Cell Based Therapies market is a valuable resource of insightful information for specific business strategists. Apart from this, it also offers an in-depth summary of the Autologous Stem Cell Based Therapies Market along with growth assessment, revenue share, demand & supply data, historical as well as futuristic amount etc. A group of research analysts offers a detailed description of the value chain and its distributors info. Moreover, the Autologous Stem Cell Based Therapies market study report delivers comprehensive information regarding the global industry that enhances the scope, understanding and application of the same.

Checkout FREE Report Sample of Autologous Stem Cell Based Therapies Market Report for Better Understanding: https://calibreresearch.com/report/global-autologous-stem-cell-based-therapies-market-4316#request-sample

Industry analysis, for an entrepreneur or a company, is a method that helps it to understand its position relative to other participants in the Autologous Stem Cell Based Therapies Market. It helps them to identify both the opportunities and threats coming their way and gives them a strong idea of the present and future scenario of the Autologous Stem Cell Based Therapies industry. The key to extant during this changing business setting is to know the variations between yourself and your competitors within the Autologous Stem Cell Based Therapies Market. The deep research study of Autologous Stem Cell Based Therapies market based on development opportunities, growth limiting factors and feasibility of investment will forecast the Autologous Stem Cell Based Therapies market growth.

Finally, The global research document on the Autologous Stem Cell Based Therapies Market discovers a large set of information regarding the competitive business environment and other substantial components. The prime aim of these major competitors is to focus on improved technologies and newer innovations.

Read this article:
Study on Autologous Stem Cell Based Therapies Market (impact of COVID-19) 2020-2026 Brainstorm Cell Therapeutics, Tigenix, Med cell Europe - Bandera...

5 tips to help clients get glowing skin in coronavirus lockdownFor many clients, achieving glowy skin in between facial appointments is sometimes easier said than done. Even with a consistentskincare routineand plenty of hydration, its easy for clients to feel like their skin isnt as radiant as it could be, especially inCovid-19 lockdown.

Help clients achieve and maintain a dewy complexion until they can see you again using make-up and skincare brandInika Organics top tips.

As you know, the first step to achieving glowing skin is to thoroughly remove all make-up and surface debris with a gentle, natural remover likePhytoactive Micellar Rosewater.

Clients should be using a product that hydrates the skin as it cleanses, removing all traces of make-up, SPF, sweat, grime and environmental pollutants. They also need to soak a cotton pad with the remover and gently wipe the face, repeating this process until the pad comes away clean.

They then need to double cleanse using a product likePhytofuse Renew Camellia Oil Cleanser, which is enriched with Rose of Jericho extract to help brighten skin and even out texture.

Once or twice a week your clients should be removing dead skin cells with a natural exfoliant. For example, Inika OrganicsPhytofuse Renewal Caviar Lime Exfoliatorwhisks away dead cells and encourages faster cell turnover, leaving skin smooth and radiant.

Ingredients such as micronised bamboo stem and pumice will deeply purify pores and refine skin texture, while natural fruit AHAs from Australian caviar lime dissolve dead cells in an instant.

Hydration is the key to unlocking radiant skin, so getting clients to invest in the rightfacial moisturiseris key they need to smooth in a few drops of a powerful facial oil likePhyto-Active Rosehip Oil Blend. Rosehip oil is extremely beneficial for skin as it provides gentle hydration, oil management, brightening of dark spots and reduced healing times.

Once your clients facial oil has been absorbed, they should then prep skin for make-up (if they decide to put some on) by massaging in a hydrating primer blended with ingredients such as hyaluronic acid, jojoba oil and kangaroo paw extract. This type of primer (i.e.Certified Organic Pure Perfection Primer)will give an even, hydrated canvas.

Build on your base with a dusting ofBaked Mineral Illuminisorin a peachy-nude shade, which is ideal for creating a glowing look. Illuminisors should be applied over the high points of the face, including the brow bone, bridge of the nose and apples of the cheeks.

Get clients to finish with a liquid highlighter that adds soft shimmer and highlights their best features. Products likeLimited Edition Liquid Glow Illuminisorcan be dabbed onto the outer edges of the eyes, cupids bow, apples of the cheeks and the bridge of the nose for an ethereal glow.

Sponsored story

Send clients this easy5-minute everyday make-up routinewhich they can practice at home.

Link:
5 tips to help clients get glowing skin in coronavirus lockdown - Professional Beauty

The report aims to provide an overview of global Autologous Stem Cell and Non-Stem Cell Based Therapies Market with detailed market segmentation by product/application and geography. The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to witness high growth during the forecast period. The report provides key statistics on the Market status of the Autologous Stem Cell and Non-Stem Cell Based Therapies players and offers key trends and opportunities in the market.

Autologous stem-cell transplantation is the autologous transplantation of stem cells. User preserves his own cells which can be used later. This is considered to be one of the effective and safer way to treat the diseases such as cancer. It is safer technology when compared with allogeneic and xeno transplants. IT reduces the risk of disease transmission, bio-incompatibility, and immunological reactions.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00006725

The Autologous Stem Cell and Non-Stem Cell Based Therapies market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cancer and diabetes, growing geriatric population, favorable reimbursement scenarios across several countries.

Top Dominating Key Players:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies market is segmented on the basis of application and end user. Based on application the market is segmented into Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases. Based on end user, the market is segmented into hospital and research institute.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Autologous Stem Cell and Non-Stem Cell Based Therapies market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Autologous Stem Cell and Non-Stem Cell Based Therapies market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Autologous Stem Cell and Non-Stem Cell Based Therapies market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00006725

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

Read the original post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis with Key Players, Applications, Trends and Forecast to 2027 - Jewish Life News

Mount Sinai Health System announced that they will be using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy, in patients with coronavirus disease 2019 (COVID-19).

Additionally, Mount Sinai indicated that they will play a central role in a clinical trial for patients with severe acute respiratory distress syndrome, which affects individuals with severe cases of COVID-19.

Remestemcel-L has previously been tested in patients who have had a bone marrow transplant, who can experience an overactive immune response similar to that observed in severe cases of COVID-19.

Mount Sinai began administering remestemcel-L to patients in late March under the FDAs compassionate use program. The therapy was given to 10 patients with moderate to severe cases of COVID-19-related acute respiratory distress syndrome (ARDS), most of whom were on ventilators, and the doctors saw encouraging results.

We are encouraged by what we have seen so far and look forward to participating in the randomized controlled trial starting soon that would better indicate whether this is an effective therapy for patients in severe respiratory distress from COVID-19, Keren Osman, MD, medical director of the Cellular Therapy Service in the Bone Marrow and Stem Cell Transplantation Program at The Tisch Cancer Institute at Mount Sinai and associate professor of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, said in a press release.

The randomized clinical trial evaluating the therapeutic benefit and safety of remestemcel-L will be conducted at Mount Sinai, which will serve as the clinical and data coordinating center. The stem cell therapy will be evaluated in 240 patients with COVID-19-related ARDS in the US and Canada. Moreover, the trial will be conducted as a public-private partnership between the Cardiothoracic Surgical Trials Network.

The coronavirus pandemic has caused exponential increases of people suffering with acute respiratory distress syndrome, requiring intubation and mechanical ventilation with many dying, Annetine Gelijns, PhD, the Edmond A. Guggenheim Professor of Health Policy at the Icahn School of Medicine at Mount Sinai, said in a press release. We have designed a clinical trial that will expeditiously determine whether the stem cell therapy will offer a life-saving therapy for a group of patients with a dismal prognosis.

Remestemcel-L consists of mesenchymal stem cells. The therapy was previously assessed in a phase III trial in children who had graft-versus-host disease (GVHD), which can occur after bone marrow transplants. Further, the inflammation that occurs in GVHD is the result of a cytokine storm. A similar cytokine storm has been found to take place in patients with COVID-19 who develop acute respiratory distress syndrome.

These stem cells have shown excellent response rates in severe graft-versus-host disease in children, John Levine, MD, professor of Hematology, Medical Oncology, and Pediatrics at the Icahn School of Medicine at Mount Sinai, who is also the co-director of the Mount Sinai Acute GVHD International Consortium (MAGIC), said in a press release. Mesenchymal stem cells have a natural property that dampens excessive immune responses.

Some institutions have also begun testing anti-IL-6 agents, such as tocilizumab (Actemra), for the treatment of cytokine release syndrome in patients with COVID-19 who develop acute respiratory distress syndrome.

Reference:

Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients [news release]. New York, NY. Published April 9, 2020. newswise.com/coronavirus/mount-sinai-leading-the-way-in-innovative-stem-cell-therapy-for-covid-19-patients/?article_id=729684&sc=dwhr&xy=10019792. Accessed April 15, 2020.

See the article here:
Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19 - Cancer Network

PHOENIX, April 20, 2020 /PRNewswire/ --Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells. The patent covers use of mesenchymal stem cells, a class of adult stem cells, for use in treatment of ovarian failure and ovarian aging.

This patent is a substantial milestone for the Company given that subsequent to filing, several academic groups published the ability of mesenchymal stem cells to treat ovarian failure in animal models.1,2

"We are pleased by the issuance of these broad claims, which not only cover a clinically-used family of stem cells, but also the cells which produce blood vessels, called Endothelial Progenitor Cells (EPC)," said Thomas Ichim, Ph.Dco-inventor and Chief Scientific Officer. "Mesenchymal stem cells isolated from a wide variety of tissues such as bone marrow, adipose tissue, umbilical cord and even teeth, have been used in clinical trials for other diseases. Given the availability, practicality and strong safety record of this class of cells, we are in a position to choose from many developmental possibilities."

Issuance adds to the existing portfolio of clinically translated adult stem cell intellectual property which include issued patents for the treatment of erectile dysfunction using bone marrow stem cells and covering treatment of disc degeneration by similar means.

According to the American Pregnancy Association:3

"Approximately1 in every 1000women between the ages of 15-29 and 1 in every 100 women between the ages of 30-39 are affected byPremature Ovarian Failure (POF)also called premature menopause. A woman can beaffected by POF at any age or time in her life. It can happen beforeor after she has had children or while she is still planning her family.

Premature ovarian failure is the loss of ovarian function in women under the age of 40. Women with POF do not ovulate (release an egg) each month. This loss of function can be due to a less than normal amount of follicles or dysfunction in the ovaries."

"The mission of Creative Medical Technology Holdings has always been to concurrently create a strong intellectual property base which is derived from ongoing basic research, while advancing our clinicallyused products such as CaverStem, StemSpine and FemCelz," said Timothy Warbington, President and CEO of the Company. "The issuance of such broad claims allows us not only to develop, but to potentially out license this landmark patent."

A "Quayle Action" is issued when there are minor issues to be resolved in a patent application that is otherwise in condition forallowance. Prosecution on the merits is closed, meaning that substantive examination has concluded.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit http://www.creativemedicaltechnology.com.

Forward Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at http://www.sec.gov.

Creativemedicaltechnology.comCaverstem.comFemcelz.comStemSpine.com

1Mohamed et al. Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure.Reprod Sci. 2018 Jan;25(1):51-63.2Badawy et al. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. Int J Womens Health. 2017 Jun 15;9:441-4473https://americanpregnancy.org/womens-health/premature-ovarian-failure/

More here:
Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action - Apache Junction News

When I first heard the word "resilience" I did not really understand what it meant, I was listening to a presentation about a third world mission trip and about how people survive their hardships there. But now, I personally understand the meaning and am ready to share my journey.

When my husband was diagnosed with cancer, I understood what may be ahead, since I am a nurse with many years of experience. The first two years of his journey were stressful, but we had each other, enjoyed our life and worked through the decisions and experience. The turning point was when he his cancer returned, and he started radiation therapy. Then, we hit what felt like a big wall.

I was diagnosed with breast cancer.

I remember sharing this news with him and he stated, "I am stronger than you think" and he proved that to be so true over the next 3 years.

Our journey together is a story of resilience, sharing hope and caring for each other. His cancer involved traveling over 3 hours to a medical center for surgery, needing an artificial airway and nutrition via a feeding tube. We spent our time together going to the local cancer center on separate days for each of our own chemotherapy treatments. As a nurse, I cared for him even during my own radiation treatment period and still kept working at my job as much as possible.

During that time, I kept thinking, is this what it takes to have that resilience? Is resilience what it takes to keep caring, maintaining hope and surviving a day at a time. If you look up the word, " resilience", there are terms like hardiness, strength and toughness. However, I have learned that it means much more.

The experience of a cancer journey together is more than what those words convey. I would often say to myself, " I am stronger than I thought too" not realizing I was beginning to understand resilience. When looking inward, you begin to understand the human spirit and what we face in life cannot truly be explained to others, but only matures every day with every hurdle we tackle and overcome.

I am a widow now and a cancer survivor, who looks back on that time in our lives, with joy of being together, with pride at how we both endured and how much stronger we became because of it. Hope was always in front of us, leading us through each day.

You should never lose hope, because that optimism is what builds the courage that leads to learning what resilience really means.

Follow this link:
Resilience Hope and Being a Survivor - Curetoday.com

We've heard that elderly people and those with underlying health conditions are most at risk if they're infected with coronavirus, but those can seem like really general terms. Who does that include? And why can they face more serious illness?"According to the , some of the underlying conditions that may put you at higher risk include: chronic lung disease and asthma, heart disease and undergoing cancer treatment," said CNN Chief Medical Correspondent Dr. Sanjay Gupta. Anyone with diabetes, kidney failure or liver failure may also be at higher risk.The role of the immune system is to protect against disease or other potentially damaging pathogens. A strong one is needed to help stave off coronavirus infection."Think of it like this," Dr. Gupta suggested. "In your everyday life, you're always fighting off pathogens. Most of the time you don't even realize it. If you have an underlying condition, it makes it more challenging to fight off a virus like this. You may develop a fever, shortness of breath or a cough more easily than someone who doesn't have a preexisting illness."Additionally, there are more specific reasons why each condition has its own vulnerabilities. Here's a guide to underlying conditions affected by coronavirus and why, and how you can protect yourself or an at-risk loved one.Older adultsEight out of 10 deaths reported in the U.S. have been in adults ages 65 and older, according to the CDC. Older adults have also been more likely to require hospitalization and admission to an intensive care unit.Older adults are more likely to have long-term health problems that can increase their risk for infection and serious disease. And, our immune systems usually weaken with age, making it more difficult for people to fight off infections, according to Johns Hopkins Medicine.The quality of our lung tissue also declines over time, becoming more elastic and making respiratory diseases such as COVID-19 of important concern because of the potential for lung damage.Inflammation in older adults can be more intense, leading to organ damage.Those with lung disease, asthma or heart conditionsPeople with chronic airway and lung diseases such as chronic obstructive pulmonary disease, asthma, pulmonary fibrosis and interstitial lung disease can lay the foundations for more severe infection with coronavirus because of the inflammation, scarring and lung damage those conditions cause, Johns Hopkins Medicine reported.COVID-19 affects a person's airway and lungs, but those organs work together to provide the body with oxygen. When the lungs are overburdened with an infection, the heart has to work harder, which exacerbates the challenges of people already living with heart disease.The immunocompromisedAccording to the CDC, many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation and immune deficiencies. Poorly controlled HIV or AIDS and prolonged use of man-made steroid hormones or other immune-weakening medications can also hamper a person's immune function.Cancer can weaken immunity by spreading into the bone marrow, which makes blood cells that help fight infection, according to Cancer Research UK. Cancer prevents bone marrow from making enough blood cells.Some cancer treatments can temporarily weaken the immune system, too. Because cancer treatments such as chemotherapy, cancer drugs, radiotherapy or steroids are targeted toward cancer cells, they can also diminish the number of white blood cells created in the bone marrow.A 2017 study found cigarette smoking can harm the immune system by either causing extreme immune responses to pathogens or rendering the body less effective at fighting disease. This may occur by smoking, negatively altering the cellular and molecular mechanisms responsible for keeping an immune system strong.When a person undergoes a bone marrow transplant using stem cells from a donor, or they receive an organ, a doctor may prescribe medications to prevent graft-versus-host disease and mitigate the immune system's reaction by suppressing its function. After the operation, it takes time for your immune system to be up and running again.HIV and AIDS attack the body's immune system, specifically the body's T cells, which help the immune system fight off infection. When the diseases are untreated, HIV reduces the number of those cells, making the person more likely to contract other infections or infection-related cancer, according to the CDC.Severe obesityPeople with severe obesity, or a body mass index of 40 or higher, are at higher risk of serious disease."Obesity shares with most chronic diseases the presence of an inflammatory component," a 2012 study said. Inflammatory responses were linked between the immune system and body fat. Obesity is known to impair immune function by altering white blood cell count as well as the cells that control immune responses.DiabetesPeople with type 1 or type 2 diabetes face an increased risk of getting really sick with COVID-19, as both cause a blood sugar spike. If blood sugar is poorly managed, viral diseases can be more dangerous as high blood sugar may give viruses a place to thrive, according to Diabetes in Control, a news and information resource for medical professionals.Higher levels of inflammation have been discovered in the bodies of people with diabetes, weakening the immune system and making it more difficult for those affected to stave off sickness in general.Kidney and liver diseaseThe kidneys produce several hormones that affect immune responses. Having kidney disease and failure can weaken your immune system, making it easier for infections to take hold. According to the National Kidney Foundation, doctors and researchers have found that most infections are worse in people with kidney disease.The liver is an integral member of the body's line of defense, helping to regulate the number of white blood cells utilized in immune responses and defend against harmful pathogens. Someone with liver disease is experiencing abnormalities in the function of the immune system, giving rise to more serious illness.Neurodevelopmental conditionsNeurological and neurodevelopmental conditions may also increase the risk of serious COVID-19 for people of any age.These include disorders of the brain, spinal cord, peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke and intellectual disability, according to the CDC. Those with moderate to severe developmental delay, muscular dystrophy or spinal cord injury are also more at-risk.People with neurological conditions may not be more at risk due to solely their condition, but because medications they might take to control their condition could hamper their immune system. However, some neurological conditions, such as Parkinson's, have been recognized to have inflammatory components, which may harm the immune system.Others including muscular dystrophy, multiple sclerosis or amyotrophic lateral sclerosis (ALS) could cause paralysis to the diaphragm, which leaves those affected very at risk for respiratory failure if they were to be sick with COVID-19.Staying safe when you're more at riskIf you see yourself on the list of those at higher risk for severe illness, there are several things you can do to protect yourself. First, make sure you are contact your doctor or doctors about your risk level. Second, be extra vigilant about the recommendations that most people are being asked to follow.Stay home whenever possible and avoid close contact with people, the CDC suggests. Wash your hands often to prevent transferring the virus from a surface to your face, and try to clean and disinfect frequently touched surfaces as often as you can.If you don't have an underlying condition, doing your part by practicing these cautionary measures can help protect not only you, but your loved ones with existing conditions.

We've heard that elderly people and those with underlying health conditions are most at risk if they're infected with coronavirus, but those can seem like really general terms. Who does that include? And why can they face more serious illness?

"According to the [Centers for Disease Control and Prevention], some of the underlying conditions that may put you at higher risk include: chronic lung disease and asthma, heart disease and undergoing cancer treatment," said CNN Chief Medical Correspondent Dr. Sanjay Gupta. Anyone with diabetes, kidney failure or liver failure may also be at higher risk.

The role of the immune system is to protect against disease or other potentially damaging pathogens. A strong one is needed to help stave off coronavirus infection.

"Think of it like this," Dr. Gupta suggested. "In your everyday life, you're always fighting off pathogens. Most of the time you don't even realize it. If you have an underlying condition, it makes it more challenging to fight off a virus like this. You may develop a fever, shortness of breath or a cough more easily than someone who doesn't have a preexisting illness."

Additionally, there are more specific reasons why each condition has its own vulnerabilities. Here's a guide to underlying conditions affected by coronavirus and why, and how you can protect yourself or an at-risk loved one.

Eight out of 10 deaths reported in the U.S. have been in adults ages 65 and older, according to the CDC. Older adults have also been more likely to require hospitalization and admission to an intensive care unit.

Older adults are more likely to have long-term health problems that can increase their risk for infection and serious disease. And, our immune systems usually weaken with age, making it more difficult for people to fight off infections, according to Johns Hopkins Medicine.

The quality of our lung tissue also declines over time, becoming more elastic and making respiratory diseases such as COVID-19 of important concern because of the potential for lung damage.

Inflammation in older adults can be more intense, leading to organ damage.

People with chronic airway and lung diseases such as chronic obstructive pulmonary disease, asthma, pulmonary fibrosis and interstitial lung disease can lay the foundations for more severe infection with coronavirus because of the inflammation, scarring and lung damage those conditions cause, Johns Hopkins Medicine reported.

COVID-19 affects a person's airway and lungs, but those organs work together to provide the body with oxygen. When the lungs are overburdened with an infection, the heart has to work harder, which exacerbates the challenges of people already living with heart disease.

According to the CDC, many conditions can cause a person to be immunocompromised, including cancer treatment, smoking, bone marrow or organ transplantation and immune deficiencies. Poorly controlled HIV or AIDS and prolonged use of man-made steroid hormones or other immune-weakening medications can also hamper a person's immune function.

Cancer can weaken immunity by spreading into the bone marrow, which makes blood cells that help fight infection, according to Cancer Research UK. Cancer prevents bone marrow from making enough blood cells.

Some cancer treatments can temporarily weaken the immune system, too. Because cancer treatments such as chemotherapy, cancer drugs, radiotherapy or steroids are targeted toward cancer cells, they can also diminish the number of white blood cells created in the bone marrow.

A 2017 study found cigarette smoking can harm the immune system by either causing extreme immune responses to pathogens or rendering the body less effective at fighting disease. This may occur by smoking, negatively altering the cellular and molecular mechanisms responsible for keeping an immune system strong.

When a person undergoes a bone marrow transplant using stem cells from a donor, or they receive an organ, a doctor may prescribe medications to prevent graft-versus-host disease and mitigate the immune system's reaction by suppressing its function. After the operation, it takes time for your immune system to be up and running again.

HIV and AIDS attack the body's immune system, specifically the body's T cells, which help the immune system fight off infection. When the diseases are untreated, HIV reduces the number of those cells, making the person more likely to contract other infections or infection-related cancer, according to the CDC.

People with severe obesity, or a body mass index of 40 or higher, are at higher risk of serious disease.

"Obesity shares with most chronic diseases the presence of an inflammatory component," a 2012 study said. Inflammatory responses were linked between the immune system and body fat. Obesity is known to impair immune function by altering white blood cell count as well as the cells that control immune responses.

People with type 1 or type 2 diabetes face an increased risk of getting really sick with COVID-19, as both cause a blood sugar spike. If blood sugar is poorly managed, viral diseases can be more dangerous as high blood sugar may give viruses a place to thrive, according to Diabetes in Control, a news and information resource for medical professionals.

Higher levels of inflammation have been discovered in the bodies of people with diabetes, weakening the immune system and making it more difficult for those affected to stave off sickness in general.

The kidneys produce several hormones that affect immune responses. Having kidney disease and failure can weaken your immune system, making it easier for infections to take hold. According to the National Kidney Foundation, doctors and researchers have found that most infections are worse in people with kidney disease.

The liver is an integral member of the body's line of defense, helping to regulate the number of white blood cells utilized in immune responses and defend against harmful pathogens. Someone with liver disease is experiencing abnormalities in the function of the immune system, giving rise to more serious illness.

Neurological and neurodevelopmental conditions may also increase the risk of serious COVID-19 for people of any age.

These include disorders of the brain, spinal cord, peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke and intellectual disability, according to the CDC. Those with moderate to severe developmental delay, muscular dystrophy or spinal cord injury are also more at-risk.

People with neurological conditions may not be more at risk due to solely their condition, but because medications they might take to control their condition could hamper their immune system. However, some neurological conditions, such as Parkinson's, have been recognized to have inflammatory components, which may harm the immune system.

Others including muscular dystrophy, multiple sclerosis or amyotrophic lateral sclerosis (ALS) could cause paralysis to the diaphragm, which leaves those affected very at risk for respiratory failure if they were to be sick with COVID-19.

If you see yourself on the list of those at higher risk for severe illness, there are several things you can do to protect yourself. First, make sure you are contact your doctor or doctors about your risk level. Second, be extra vigilant about the recommendations that most people are being asked to follow.

Stay home whenever possible and avoid close contact with people, the CDC suggests. Wash your hands often to prevent transferring the virus from a surface to your face, and try to clean and disinfect frequently touched surfaces as often as you can.

If you don't have an underlying condition, doing your part by practicing these cautionary measures can help protect not only you, but your loved ones with existing conditions.

More:
What are the underlying conditions causing more serious illness from coronavirus? - KSBW The Central Coast

Reprinted with permission fromWorld At Large, a news website which covers politics, nature, science, health, and travel.

Age-related macular degeneration (MD) is a variety of ocular disease that affects so many millions of people, its downright characterized as nothing more than the process of aging.

In fact, the study of MD has proven itself to be so fruitful for understanding aging as a whole, MD has become one of the first places that scientists have looked to in order to attempt to repair the damage of aging and restoring youthful, or normal function.

Now in a new paper published in Nature, researchers demonstrate an alternative to stem cells by creating replacement photoreceptors from skin fibroblast cells via pharmacological-conversiona process that promises to be cheaper, faster, and unburdened by ethical and legal restrictions.

Containing the genetic code for every protein we need to build and repair our cells, DNA can become damaged over time through the stresses of life. Similarly to how scratches or cracks in a CD prevent lasers from reading the information on the disk, damaged DNA becomes difficult, and even impossible for our RNA (which you could imagine as the laser inside the CD player) to read the genetic information contained therein.

WATCH: Blind Man Develops Smart Cane That Uses Google Maps and Sensors to Identify Ones Surroundings

The photoreceptor is the neuron in the eye that turns on visual circuity in response to light which enables us to have vision, says Sai Chavala, Ph.D. and author of the new paper.

The loss of photoreceptors can result in MD and other retinal diseases that lead to irreversible blindness. In this new study, however, cells called fibroblasts can be chemically reprogrammed to produce photoreceptor-like cells that are now shown to restore vision in mice.

Fibroblasts are cells that help maintain the structural integrity of connective tissues, and a reduction in fibroblast cell count leads to wrinkled skin.

Sai Chavala and colleagues from the Center for Retina Innovation in Dallas, Texas, found a set of five compounds that can drive embryonic fibroblast cells to convert themselves into retinal, rod-like, photoreceptors in both mice and human cells.

Stem cell-based strategies are extremely exciting, Dr. Chavala tells World at Large, but adds that generating these cells can be cumbersome and time-consuming. Describing his strategy of chemically reprogramming existing cells as a breakthrough, Chavala added that the generation of the photoreceptors using his method requires a fraction of the time.

In the study, these converted photoreceptors were transplanted into the eyes of 14 blind mice to see if they would restore vision.

CHECK OUT: LEGO Unveils New Bricks That Will Help Teach Blind Children to Read Braille

Owing to their nature, mice with working vision prefer dark spaces, and so a test of whether or not the transplant was a success was fairly straight forward; create a bright space and a dark space and wait to see which one was preferred by the mice.

Six mice were found to not only have restored visual function and reflexesnotably in the pupilbut they also preferred to spend their time in the dark space. Chavala hypothesizes that it could have been down to how many of the chemically-reprogrammed cells survived the transplant into the retina that determined whether vision was restored in the mice or not.

What makes interventions like thesewhich involve creating brand new cells to replace the damaged onesso effective and exciting in the field of aging is that they present an alternative to natural replication by bypassing the difficulties that our own cells have with trying to repair themselves from DNA that features double-strand breaks or other blemishes.

Adding that these conversions of fibroblasts to photoreceptors has also been done in humans, Chavala detailed why he believes the treatments and future research to spring from this discovery are going to change the field of ophthalmology.

CHECK OUT: In World First Blind People Have Their Vision Restored Thanks to Stem Cells From Deceased Organ Donors

We [] believe this can be a game changer in the field of regenerative ophthalmology. We also believe this is a platform technology and have already started establishing protocols to generate retinal ganglion cells valuable for patients suffering from glaucoma, says Chavala.

In addition to bypassing the ethical and political restrictions and hiccups with using embryonic human stem cells, the process takes two weeks, costs less, and is more scalable than using stem cells.

WATCH: Hundreds of People Are Being Cured of Blindness Every Day With Cheap, Minutes-Long Surgery

It is intriguing to postulate that the addition of other molecules or modifications to the culture conditions can yield other types of neurons beneficial for a variety of neurological diseases, he adds, discussing possible alternatives to photoreceptor generation from fibroblasts.

Finally, Chavala is rapidly approaching human trials and hopes to have an FDA-approved treatment out the other end of the pipeline in 2-3 years, saying he is thrilled with the possibility of allowing millions of people to regain their lost vision.

Its Not Hard To See That You Should Share This Good News With Your Friends On Social Media

Read the original here:
Irreversible No Longer: Blind Mice See Again Thanks To New Method of Synthesizing Lost Cells - Good News Network

First Posted: Apr 20, 2020 06:30 AM EDT

Almost every month, a new beauty fad takes over the world. Beauty products with activated charcoal have become a household name since it hit the market. Thanks to its ability to unclog pores and remove dirt, bacteria, and all kinds of nasties on the skin's surface, the ingredient has made a name for itself in the beauty world.

By definition, activated charcoal is charcoal that has been treated so it can attract and trap toxins in our bodies before they are absorbed. On the skin's surface, it acts as a magnet for oils, dead skin cells, and dirt from environmental exposure.

Charcoal is known for its diverse uses--whitening teeth and reducing acne, leaving your skin bright and clear. Here are some products with activated charcoal that you must have:

(Photo: Amazon)

Biore's Deep Pore Charcoal Cleanse formula is a dermatologically tested product that lifts away dirt and oil on the skin without all the harsh chemicals. It comes in an easy-to-use pump bottle that provides just the right amount of product for every wash.

Biore's cleansing formula leaves your skin glowing and bright with a cooling menthol effect. It's oil-free, vegan-friendly, cruelty-free, and paraben-free. So if you're looking for something that leaves your face feeling deeply clean, then this product is perfect for you.

(Photo: Amazon)

Biore's Cleansing Pore Strips work like magic in extracting all that unwanted dirt in clogged pores. A strip could easily remove all those nasty blackheads from your nose. The cleansing pore strips are easy to apply and will leave your skin feeling spotless.

For best results, it is recommended to wash your face with warm water to relax and open up the pores before applying a strip. It is also advised to dry your hands before using the piece as it does not stick well to wet surfaces.

(Photo: Amazon)

Colgate's Charcoal Toothpaste effectively whitens teeth and removes impurities that can contribute to surface stain. The product has a great texture and suds up well. Colgate's formula contains micro polishers that leave a whiter, brighter smile, and long-lasting fresh breath.The formula contains essential ingredients to keep your teeth safe from cavities. Use daily for best results.

(Photo: Amazon)

M3 Natural Activated Charcoal Scrub is an all-natural scrub that can be used on the body and the face. The formula is infused with dead sea salt that's effective for extracting and removing excess oil and dirt deep inside the pores. It also contains collagen and stem cells to deliver a powerful anti-aging effect.

The product has been admired for being friendly to acne-prone skin. It's safe, natural, and proven effective. A jar of M3's Activated Charcoal Scrub provides about a month's worth of product.

For best results, apply on damp skin with a circular scrubbing motion. Using a body brush can also increase the scrubbing effect and stimulation to provide a healthy and glowing complexion.

Looking for other products? Check these out:

TagsAmazon, amazon deals, beauty products, activated charcoal

2015 Latin Post. All rights reserved. Do not reproduce without permission.

Link:
4 Charcoal Beauty Products That Actually Work - Latin Post

The report aims to provide an overview of global Autologous Stem Cell and Non-Stem Cell Based Therapies Market with detailed market segmentation by product/application and geography. The global Autologous Stem Cell and Non-Stem Cell Based Therapies Market is expected to witness high growth during the forecast period. The report provides key statistics on the Market status of the Autologous Stem Cell and Non-Stem Cell Based Therapies players and offers key trends and opportunities in the market.

Autologous stem-cell transplantation is the autologous transplantation of stem cells. User preserves his own cells which can be used later. This is considered to be one of the effective and safer way to treat the diseases such as cancer. It is safer technology when compared with allogeneic and xeno transplants. IT reduces the risk of disease transmission, bio-incompatibility, and immunological reactions.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00006725

The Autologous Stem Cell and Non-Stem Cell Based Therapies market is anticipated to grow in the forecast period owing to driving factors such as rising prevalence of cancer and diabetes, growing geriatric population, favorable reimbursement scenarios across several countries.

Top Dominating Key Players:

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies market is segmented on the basis of application and end user. Based on application the market is segmented into Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases. Based on end user, the market is segmented into hospital and research institute.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Autologous Stem Cell and Non-Stem Cell Based Therapies market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Autologous Stem Cell and Non-Stem Cell Based Therapies market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Autologous Stem Cell and Non-Stem Cell Based Therapies market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00006725

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

View post:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis and 2027 Forecasts for United States, Europe, Japan and China Markets - Science...

When our panelists were asked which innovation showed the best results, scalp injections of platelet-rich plasma (PRP) for hair growth was at the top of many lists. You get significant benefits with very little downside, Dr. Schultz says. First, your blood is drawn and spun in a centrifuge to separate the PRP, which is then injected all over your scalp. Using your bloods growth factors to stimulate collagen and follicles lets your own body work its magic, says dermatologist Mona Gohara, M.D.

Another new option is a laser called Lutronic KeraLase ($750 to $1,000 per treatment), which is paired with a synthetic growth factor serum. The device stamps across your scalp, stimulating the area and creating tiny channels in the follicles, where the serum is then applied. It delivers active ingredients where theyre needed, says dermatologist Jeanine Downie, M.D. The serum can contain even more growth factors than a persons own PRP, plus stem cells to help hair growth, she says. Nutrafol for Women (Buy It, $79 $88 for 1 month, nutrafol.com), a supplement brand for hair loss, also garnered multiple mentions from our panel. Ive seen promising results, especially in conjunction with the above treatments, Dr. Downie says.

See original here:
The Best Face and Body Skin-Care Products for 2020 - Shape Magazine

The Food and Drug Administration approved Tukysa, which is indicated for use with two other drugs after patients have completed treatment with prior therapies targeting the protein HER2.

Tukysa inhibits the protein HER2, whose overexpression is a driver of this type of breast cancer. Under the approval, the drug will be given along with another HER2 inhibitor, Herceptin (trastuzumab), and the chemotherapy capecitabine. The Tukysa regimen is meant for use after patients have completed treatment with one or more therapies containing an anti-HER2 drug.

The approval was based on findings from a clinical trial that included 612 patients with advanced or metastatic HER2-positive breast cancer, including some whose disease had spread to the brain. Patients who took the Tukysa combination went a median 7.8 months before experiencing disease progression, compared with 5.6 months in patients in the two-drug group. In the Tukysa group, the median overall survival was 21.9 months compared with 17.4 months in the placebo/Herceptin/capecitabine group.

Common side effects associated with Tukysa were diarrhea, burning or tingling discomfort in the hands and feet, nausea, fatigue, liver damage, vomiting, inflammation of the mouth and lips, decreased appetite, abdominal pain, headache, anemia and rash. Tukysa can also cause serious side effects including severe diarrhea associated with dehydration, acute kidney injury and death.

The FDA nod was part of Project Orbis, which allows drug developers to seek approvals from the governments of multiple countries simultaneously. In this case, the FDA collaborated with drug authorities in Australia, Canada, Singapore and Switzerland. However, Tukysa was still under review in those countries as of April 17.

Tukysa was approved four months prior to the FDAs goal date, according to Dr. Richard Pazdur, director of the agencys Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in its Center for Drug Evaluation and Research. He said the early approval was an example of the FDAs commitment to expediting oncology drug development despite challenges posed by the COVID-19 pandemic and showing how their work to approve cancer therapies was not being delayed.

Check back later for what you need to know about this approval.

Follow this link:
FDA Approves Tukysa to Treat Advanced or Metastatic HER2-Positive Breast Cancer - Curetoday.com

MD Stem Cells reports results for Dry AMD from their clinical study SCOTS - the Stem Cell Ophthalmology Treatment Study. 63% of treated and evaluated eyes achieved improvement in vision while an additional 34% had vision remain stable in follow up. No complications occurred. Results were statistically significant.

Westport, CT, April 18, 2020 --(PR.com)-- Age Related Macular Degeneration - specifically dry AMD - will affect almost 200 million people worldwide in 2020. An approach, pioneered by MD Stem Cells, using bone marrow stem cells from the actual patient has now shown visual improvement for 63% of dry AMD eyes and stability in another 34%, demonstrating statistical significance in helping patients with this blinding disease. Results were recently published in the Medicines Journal - a highly regarded international medical journal. The title of the paper: Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration.

There is no FDA approved medication for treating dry AMD. Certain vitamins may reduce the risk of bleeding or wet AMD. But vitamins do not appear to stop the relentless loss of retinal cells and vision called geographic atrophy (GA) from AMD.

The highlight of the MD Stem Cell report was that 63% of dry AMD eyes treated and followed had vision improvement. This ranged from 2.5% to 44.6% with an average of 27.6% on a scientific vision scale called LogMAR. An additional 34% of eyes remained stable for the follow up period- important because many of the eyes had previously been losing vision. The findings were highly statistically significant with p < 0.001 meaning that the results overwhelmingly met that medical standard and confirming that the BMSC treatment was responsible for the improvements seen.

The Stem Cell Treatment Ophthalmology Study- both SCOTS and SCOTS2 - has been treating many different eye diseases since 2013 using the patients own bone marrow stem cells (BMSC) injected in the orbit around the eye. The study is Institutional Board Approved and National Institutes of Health registered on http://www.clinicaltrials.gov NCT 03011541. The physicians involved with MD Stem Cells now have 14 world class medical and scientific publications primarily reporting their clinical results in ophthalmology. This is vastly more than any other stem cell research group working with eye disease and should be reassuring to patients and health care providers seeking treatment options. Different optic nerve diseases, NAION, LHON, DOA, optic atrophy; as well as several retinal diseases including Retinitis Pigmentosa, Ushers and now AMD have all shown benefit. MD Stem Cells has worked to achieve the safest, most effective approach to dry AMD using BMSC - with gratifying success.

Following multiple patient treatments and over a dozen peer-reviewed papers, our studies have shown that a patients own bone marrow stem cells (BMSC) can have positive effects on different retinal and optic nerve diseases, explains Dr. Levy, CEO and Chief Science Officer for MD Stem Cells. As we have continued the study, other researchers have published numerous papers revealing how this may be occurring: release of exosomes with neurotrophic factors helping neurons and photoreceptors, transfer of cytoplasmic structures such as mitochondria to injured cells, and transdifferentiation of BMSC into neurons.

Dr. Levy concludes: The research has shown that patients with dry AMD choosing to participate in the SCOTS 2 may have a significant likelihood of either improving or stabilizing their vision.

Patients may receive information about SCOTS 2 by emailing stevenlevy@mdstemcells.com, using the contact us page on http://www.mdstemcellscom, or calling 203-423-9494. The Stem Cell Ophthalmology Study 2 is enrolling patients with different retina and optic nerve diseases. MD Stem Cells has no grant support and is not a pharmaceutical company; these are patient sponsored studies and the patients pay for both treatment and travel.

Contact Information:MD Stem CellsSteven Levy MD203-423-9494Contact via Emailwww.mdstemcells.com

Read the full story here: https://www.pr.com/press-release/810435

Press Release Distributed by PR.com

Continue reading here:
New Treatment Shows Vision Benefit in Age Related Macular Degeneration - Benzinga

Sleep, diet, exercise, and stress: these are factors known to change a persons risk of developing numerous non-communicable diseases. Such lifestyle impacts on healthbeneficial or harmfulexert much of their influence via inflammation. About 10 years ago, Matthias Nahrendorf began wondering just how inflammation and lifestyle might be linked biologically, and started thinking about how to pinpoint the mechanism in the cardinal case of cardiovascular disease.

A persons level of inflammation can easily be measured with a simple white blood cell test. White blood cells fight off bacterial invasions and repair damaged tissues, but they can also damage healthy tissue when they become too abundant. You can find them in atherosclerotic plaques, and you can find them in acute infarcts, says Nahrendorf, a professor of radiology who conducts high-resolution imaging research at Massachusetts General Hospital. You can find them in failing hearts and the brain, where they increase the risk of stroke.

By linking exercise to reduced white blood cell production, Nahrendorf shows how a lifestyle factor can modulate cardiovascular risk.

When Nahrendorf learned that the most potent, toxic, and pro-inflammatory white blood cells live only a few hours, or at most a day, he immediately realized that the paramount questionsgiven that they die off quickly yet remain abundant in the bloodare, where and why are they produced? What is their source? Perhaps, he hypothesized, lifestyle factors regulate hematopoiesis (blood production).

To test this idea, he decided to study the effects of exercise on the production of these leukocytes in healthy mice. First, though, he consulted the scientific literature on exercise in mice. Previous researchers, he learned, had found that exercise increases production of inflammatory immune cellswhich I thought was counterintuitive, Nahrendorf recalls. When he looked more carefully, he discovered that the type of exercise used in the studies was forced and thus possibly stressful because it was induced by electric shocks. He therefore decided to test only voluntary exercise. He and his colleagues put a wheel in each mouses cage, so the animals could choose to run if they were interested.

The mice never ran during the day. That is when they rest, Nahrendorf explains. But in the dark, they ran a lot, averaging six to seven miles every night. After three weeks, the exercising mice had measurably lower levels of circulating white blood cells. Exercise, he found, had pushed their blood stem cells (cells that can produce all the different types of blood cells) into a state of quiescence: a kind of dormancy in which they generate fewer pro-inflammatory white blood cells and platelets, without decreasing the number of oxygen-carrying red blood cells. Soon the exercising mice had fewer circulating white blood cells than their sedentary counterparts, dampening inflammationan effect that persisted for weeks.

The local signals within bone marrow that induce quiescence in blood stem cells were already well known, but the fact that exercise could trigger them was not. Nahrendorf next wanted to learn the identity of the trigger linking exercise to blood stem cell quiescence. Further investigation revealed that the only receptors with enhanced activity in the bone marrow niche where most blood stem cells exist were binding to a well-known hormone called leptin; it is produced by fat cells and regulates hunger.

Leptin is like the fuel gauge in a car. When the tank is fullmeaning energy (and food) are abundantleptin levels run high. As exercise uses up the gas in the tank, this lowers leptin levels, which signal that reserves are running low, thereby inducing hunger and the urge to eat in order to replenish depleted energy stores. Nahrendorf and his co-authors speculate in their 2019 Nature Medicine paper that leptins role in regulating energetically costly hematopoiesis may have evolved to produce blood cells only when whole body energy was abundantnot when people are exerting themselves. Contemporary sedentary behavior, they continue, which increases leptin and consequently hematopoiesis, may have rendered this adaptation a risk factor for cardiovascular disease (CVD) and perhaps also for other diseases with inflammatory components.

But with fewer circulating immune cells, would exercising mice be more vulnerable to infection? Nahrendorf challenged them with a protocol designed to induce infection in the blood, and found just the opposite: exercising mice had a more robust immune response, as semi-dormant blood stem cells swiftly sprang into activity and produced infection-fighting leukocytes, improving survival of the active mice as compared to those with no running wheels in their cages. Next, they investigated whether exercise would help mice with established atherosclerosis, and found that exercise was not only protective, it also reduced the size of existing plaques in the aorta.

Whether these associations would hold up in humans remained an open question. For answers, Nahrendorf turned to a study known as CANTOS, which had measured levels of inflammation in 4,892 patients who suffered heart attacks (see Raw and Red Hot, May-June 2019, page 46). When he approached the studys co-authors, Mallinckrodt professor of medicine Peter Libby and Braunwald professor of medicine Paul Ridker, he learned, serendipitously, not only that they possessed self-reported exercise levels for the participants, but also that they had tested leptin levels as well. They analyzed their raw data and found the same relationship among exercise, leptin, and leukocytes as in the mice. Data from a second human study cemented the result.

By identifying a previously unknown molecular mechanism linking voluntary exercise to reduced white blood cell production, Nahrendorf and his colleagues have highlighted how a lifestyle factor can modulate cardiovascular risk. Their discovery, the researchers hope, will point the way to wider adoption of healthy exercise regimens, and health-enhancing anti-inflammatory drugs.

Link:
Stem cell activity linked to lifestyle - Harvard Magazine

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-market-to-2027---global-analysis-and-forecasts-by-type-treatment-application-end-user-and-geography-301041155.html

SOURCE Reportlinker

View post:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - P&T Community

The "Orphan Drugs Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering.

The global orphan drugs market was worth $132.61 billion in 2019. North America is expected to be the largest region during the period 2015-2023. Major players in the market are Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche, Amgen, Biogen, Bayer, Novartis, GlaxoSmithKline, Johnson & Johnson and AbbVie.

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider orphan drugs market, and compares it with other markets.

The rising prevalence of rare diseases is a key factor driving the growth of the orphan drugs market.

Orphan diseases or rare diseases occur rarely among the people (i.e. 7 out of 10,000). However, globally, the prevalence of rare diseases is increasing in recent years. In 2017, there were 7,000 identified rare diseases, including hemophilia, Gaucher disease, Hunter syndrome and many types of rare cancer. Some cases of aplastic anemia, caused by damage to stem cells in the bone marrow that are diagnosed in around 500 to 1,000 individuals in the USA each year, are inherited. Thus, the rising prevalence of rare diseases is driving the growth of the orphan drugs market.

Lack of supportive government policies hinders the orphan drugs market.

Due to the lack of relevant policies for orphan drug, certain drugs do not receive any special recognition or priorities for approval by regulatory authority. Medgenome Labs Ltd., global research partner in accelerating insights into complex genetic diseases, pointed out that companies manufacturing orphan drugs frequently drop out in foreign markets due to a lack of government funding. For example, orphan medical products (OMPs) in India, due to lack of proper regulations and clear guidelines, do not obtain tax cuts or exemptions from customs duties. Therefore, lack of supportive government policies limits the growth of the orphan drugs market.

Approval of biological orphan drugs for multiple indication act as a key trend driving the growth of the orphan drugs market.

The biological drugs are used for treating rare diseases such as cancer with fewer side effects that have a high prevalence rate in the developed world. For Instance, in 2018, in order to launch the company's biological orphan drug development program Cardax, Inc. announced that it has been engaged with biological orphan drug expert Frederick D. Sancilio, Ph.D. For the development of commercial products, the companies are focused on obtaining biological orphan drugs to increase their revenue.

In November 2019, Bristol-Myers Squibb, a biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines, acquired Celgene for an undisclosed amount. Through this acquisition, Celgene shareholders received for each share, 1 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Celgene, a biopharmaceutical company positioned to address the needs of the patients with serious diseases.

Key Topics Covered

1. Executive Summary

2. Orphan Drugs Market Characteristics

3. Orphan Drugs Market Size and Growth

3.1. Global Orphan Drugs Historic Market, 2015-2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Orphan Drugs Forecast Market, 2019-2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Orphan Drugs Market Segmentation

4.1. Global Orphan Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Orphan Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Orphan Drugs Market Regional and Country Analysis

5.1. Global Orphan Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Story continues

5.2. Global Orphan Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/vm9iey

View source version on businesswire.com: https://www.businesswire.com/news/home/20200417005515/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the article here:
Orphan Drugs Market Insights, 2020: Approval of Biological Orphan Drugs for Multiple Indications is Driving Market Growth - ResearchAndMarkets.com -...

Many in the medical community view an experimental antiviral drug called remdesivir, manufactured by Gilead Sciences, as the best chance for a treatment. In tests in academic labs, in work sponsored by the federal government, it has been shown to block viral replication. A clutch of clinical trials are underway worldwide to test it in patients, and Gilead is distributing it to thousands of people on a "compassionate use" basis. Remdesivir is considered a broad-spectrum antiviral, meaning it is believed to work against multiple types of virus. But it failed in a test against Ebola last year. Also, it has a big drawback: It is a liquid that must be given intravenously, which means people must go to a hospital or clinic on 10 consecutive days to be treated. Gilead, the National Institutes of Health and the World Health Organization are among those sponsoring multiple clinical trials, and preliminary results are expected within weeks.

Continued here:
Here are the drugs that could treat coronavirus. But don't expect a silver bullet. - The Philadelphia Inquirer

-Spinal cord injury (SCI) creates a complex microenvironment that is not conducive to repair; growth factors are in short supply, whereas factors that inhibit regeneration are plentiful. In a new report, researchers have developed a structural bridge material that simultaneously stimulates IL-10 and NT-3 expression using a single bi-cistronic vector to alter the microenvironment and enhance repair. The article is reported in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the article for free on the Tissue Engineering website through May 17, 2020.

In Polycistronic Delivery of IL-10 and NT-3 Promotes Oligodendrocyte Myelination and Functional Recovery in a Mouse Spinal Cord Injury Model, Lonnie D. Shea, PhD, University of Michigan, and coauthors report the development of a new poly(lactide-co-glycolide) (PLG) bridge with an incorporated polycistronic IL-3/NT-3 lentiviral construct. This material was used to stimulate repair in a mouse SCI model. IL-10 was included to successfully stimulate a regenerative phenotype in recruited macrophages, while NT-3 was used to promote axonal survival and elongation. The combined expression was successful; axonal density and myelination were increased, and locomotor functional recovery in mice was improved.

Inflammation plays a vital role in tissue repair and regeneration, and the use of a PLG bridge to take advantage of the inflammatory response to promote SCI repair is an elegant way to take advantage of these natural processes to improve SCI healing, says Tissue Engineering Co-Editor-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX.

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Leadership of Tissue Engineering Parts B (Reviews) and Part C (Methods) is provided by Katja Schenke-Layland, PhD, Eberhard Karls University, Tbingen, Heungsoo Shin, PhD, Hanyang University; and John A. Jansen, DDS, PhD, Radboud University, and Xiumei Wang, PhD, Tsinghua University respectively. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms 90 journals, books, and newsmagazines is available on the e Mary Ann Liebert, Inc., publishers website.

Read the original:
Co-delivery of IL-10 and NT-3 to Enhance Spinal Cord Injury Repair - Mirage News

Northwestern University scientists received top honors from the Clinical Research Forum as part of its 2020 Top Ten Clinical Research Achievement Awards program, taking home the associations highest honor and capturing more finalist nominations than any other institution.

The remarkable success of these brilliant and dedicated investigators shows the strength and breadth of Northwesterns clinical research program and demonstrates our shared commitment as an institution to groundbreaking science that transforms human health, said Eric G. Neilson, MD, vice president for medical affairs and Lewis Landsberg Dean, Northwestern University Feinberg School of Medicine.

John Rogers, PhD, the Louis Simpson and Kimberly Querrey Professor of Materials Science and Engineering, Biomedical Engineering and Neurological Surgery, was awarded the prestigious Herbert Pardes Clinical Research Excellence Award for the research study that best shows a high degree of innovation and creativity, advances science and has an impact upon human disease.

Richard Burt, MD, chief of Immunotherapy and Autoimmune Diseases in the Department of Medicine, was chosen to receive the Distinguished Clinical Research Award. Norrina Allen, PhD, associate professor of Preventive Medicine in the Division of Epidemiology, and Daniela Matei, MD, the Diana, Princess of Wales Professor of Cancer Research and a professor of Medicine in the Division of Hematology and Oncology, were also named to the list of top 20 finalists.

Rogers and Burt are members of the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. The Clinical Research Forum, an organization dedicated to supporting the clinical translational research enterprise and promoting understanding and support for clinical research and its impact on health and healthcare, celebrates outstanding research accomplishments that exemplify innovation and impact on human disease.

Northwestern studies honored by the Clinical Research Forum are:

Skin-like Devices for Wireless Monitoring of Vital Signs in Neonatal Intensive Care (John Rogers, PhD), published in Science. Reporting on the development and validation of a pair of soft, flexible wireless sensors that replace the tangle of wire-based sensors that currently monitor babies in hospitals neonatal intensive care units. The study concluded that that the wireless sensors provided data as precise and accurate as that from traditional monitoring systems, and were gentler on a newborns fragile skin and allow for more skin-to-skin contact with the parent, which has been shown to improve the health of infants and promote emotional bonding.

Hematopoietic Stem Cell Transplantation for Frequently Relapsing Multiple Sclerosis (Richard Burt, MD), published in JAMA. Reporting the success of a process called hematopoietic stem cell transplantation, which temporarily shuts down and reboots patients immune systems with the application of a patients own stem cells, this study demonstrated significant improvement over the current therapies. The study found benefits for patients which no drug had been able to accomplish before.

Associations of Dietary Cholesterol or Egg Consumption with Incident Cardiovascular Disease and Mortality (Norrina Allen, PhD), published in JAMA.

The results of this large study found that adults who ate more eggs and dietary cholesterol had a significantly higher risk of cardiovascular disease and death from any cause.

The study suggested that current U.S. dietary guideline recommendations for dietary cholesterol and eggs, one of the richest sources of dietary cholesterol among all commonly consumed foods, may need to be re-evaluated.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer (Daniela Matei, MD), published in New England Journal of Medicine.

This study found that radiation combined with chemotherapy did not increase recurrence-free survival in women with stage III/IVA endometrial cancer, normally the standard of care in these cases.

Endometrial cancer, which begins in the uterus, is the most common gynecologic cancer with most cases occurring in women after age 55, and both occurrence of and mortality from the disease are rising.

Nominees and Top Ten Awardees were announced at the end of January, and the Herbert Pardes Clinical Research Excellence Award and the Distinguished Clinical Research Achievement Awards were announced virtually on April 15.

Learn more about Northwestern University Feinberg School of Medicine at https://www.feinberg.northwestern.edu/.

Read more:
Northwestern Scientists Awarded Top Honors for Achievement in Clinical Research - Northwestern University NewsCenter